This study systematically reviews the efficacy and safety of combining transarterial embolization (TAE) with radiotherapy (RT) for managing bone metastases (BM), assessing clinical response (CR), and local control (LC). A literature search using PubMed, Scopus, Web of Science, Medline Plus, and the Cochrane Library identified three relevant studies with 74 patients and 103 BM. One study included local chemotherapy infusion with TAE. All studies reported CR rates, though one used skeletal-related events as a surrogate, while only one study provided LC rates. Adverse events were noted across all studies. A quantitative analysis of CR rates showed a relative risk (RR) of 0.15 (confidence interval (CI): 0.03–0.69) favoring TAE plus RT over RT alone, while no significant differences were observed between TAE plus RT and TAE alone (RR: 0.91; CI: 0.51–1.63). The combined TAE and RT approach demonstrated effectiveness in local tumor control and produced faster, longer-lasting pain relief than RT alone, although TAE was associated with a mild, transient increase in side effects. While TAE plus RT shows potential benefit and acceptable toxicity, the current evidence is of low quality.
本研究系统评价了经动脉栓塞术（TAE）联合放射治疗（RT）在骨转移瘤（BM）管理中的疗效与安全性，并对临床缓解率（CR）及局部控制率（LC）进行了评估。通过检索PubMed、Scopus、Web of Science、Medline Plus及Cochrane Library数据库，共纳入三项相关研究，涉及74例患者及103处骨转移灶。其中一项研究在TAE基础上联合了局部化疗灌注。所有研究均报告了临床缓解率，但一项研究以骨骼相关事件作为替代指标，仅有一项研究提供了局部控制率数据。所有研究均记录了不良事件。对临床缓解率的定量分析显示，TAE联合RT相较于单纯RT的相对风险（RR）为0.15（置信区间[CI]：0.03–0.69），表明联合治疗更具优势；而TAE联合RT与单纯TAE相比则未观察到显著差异（RR：0.91；CI：0.51–1.63）。TAE联合RT的治疗策略在局部肿瘤控制方面显示出有效性，且相较于单纯RT能更快、更持久地缓解疼痛，尽管TAE可能伴随轻微、短暂的不良反应增加。尽管TAE联合RT显示出潜在获益且毒性可接受，但现有证据质量较低。
肿瘤(癌症)患者之家